Cohort D of the CARITUDE-2 trial evaluated the efficacy and safety of cilta-cel ± lenalidomide maintenance in patients with multiple myeloma who had <CR to frontline autologous stem celltransplant. Seventeen patients receivedalimidemaintnaneand patnts that ddntivedlalmidemaintnanceexpei gradortiocaf grademldyplasti srmwitantdaywasrprtdand t were no deaths dues to TEAEs. CRS of any grade was reported in 14% of patients with no patients experience grade 3 or 4 CRS. The median time to CRS onset and duration was 8 days and 2.5 days, respectively. One patient